Drug Details
| General Information of the Drug (ID: DR5958) | ||||
|---|---|---|---|---|
| Name |
SMC3
|
|||
| Synonyms |
Smac mimetic compound 3
Click to Show/Hide
|
|||
| Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | |
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Luteolin | Abrus precatorius | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SOD Mn | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H23 | CVCL_1547 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Attenuating Smac mimetic compound 3-induced NF-kappaB activation by luteolin leads to synergistic cytotoxicity in cancer cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Sphingolipid delta(4)-desaturase DES1 (DEGS1) | Molecule Info | [3] | |
